These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7734313)

  • 41. High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer.
    Sleijfer S; Van der Graaf WT; Willemse PH; De Vries EG; Schraffordt Koops H; Mulder NH
    Anticancer Res; 1995; 15(3):1039-42. PubMed ID: 7544087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
    Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines.
    Wilson C; Yang J; Strefford JC; Summersgill B; Young BD; Shipley J; Oliver T; Lu YJ
    Genes Chromosomes Cancer; 2005 Jun; 43(2):211-6. PubMed ID: 15761863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
    Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
    Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs).
    Pliarchopoulou K; Pectasides D
    Cancer Treat Rev; 2009 Nov; 35(7):563-9. PubMed ID: 19576697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs.
    Masters JR; Osborne EJ; Walker MC; Parris CN
    Int J Cancer; 1993 Jan; 53(2):340-6. PubMed ID: 8425772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
    Chen M; Osman I; Orlow SJ
    Mol Cancer Res; 2009 May; 7(5):703-12. PubMed ID: 19435820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O; Siegert W; Beyer J
    Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report).
    Sakalo VS; Korsh OB; Melnyk A
    Drugs Exp Clin Res; 1996; 22(3-5):263-5. PubMed ID: 8899344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term side effects of chemotherapy for testicular cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1300-5. PubMed ID: 12146015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
    Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
    J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
    Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
    Int J Urol; 2004 Sep; 11(9):768-73. PubMed ID: 15379942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
    Tsang LL; Farmer PB; Gescher A; Slack JA
    Cancer Chemother Pharmacol; 1990; 26(6):429-36. PubMed ID: 2225314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ifosfamide in the treatment of germ cell tumors.
    Nichols CR
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.
    Koul S; McKiernan JM; Narayan G; Houldsworth J; Bacik J; Dobrzynski DL; Assaad AM; Mansukhani M; Reuter VE; Bosl GJ; Chaganti RS; Murty VV
    Mol Cancer; 2004 May; 3():16. PubMed ID: 15149548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.